[HTML][HTML] Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated …
Journal of clinical oncology, 2010•ncbi.nlm.nih.gov
Purpose We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic
colorectal cancer (mCRC), and changes during treatment in plasma cytokines and
angiogenic factors (CAFs) as potential markers of treatment response and therapeutic
resistance.
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic
colorectal cancer (mCRC), and changes during treatment in plasma cytokines and
angiogenic factors (CAFs) as potential markers of treatment response and therapeutic
resistance.
Abstract
Purpose
We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers of treatment response and therapeutic resistance.
ncbi.nlm.nih.gov